Document Detail


Mammalian target of rapamycin (mTOR) Inhibitors.
MedLine Citation:
PMID:  14751088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle. Rapamycin is the first defined inhibitor of mTOR, and the demonstration of its antitumor activity has led to great interest in this pathway as an antitumor mechanism. Analogues with better pharmacologic properties have been developed and have entered clinical trials. Human cell lines of renal cell cancer, among several other tumors, are sensitive to growth inhibition via this pathway. Ongoing clinical trials are evaluating renal cell cancer and other malignancies using therapy with mTOR inhibitors. These agents are more likely to induce growth inhibition rather than tumor regression.
Authors:
Janice P Dutcher
Related Documents :
2190998 - Phosphorylation-related accumulation of the 125k nuclear matrix protein mitotin in huma...
362178 - Cell-cycle variation in the induction of lethality and mitotic recombination after trea...
2985878 - Glucocorticoid receptors of normal and leukemic cells: role of proliferation conditions.
3801408 - Expression of growth-regulated genes in tsjt60 cells, a temperature-sensitive mutant of...
7051368 - Immunopotentiation of anticancer chemotherapy by candida albicans, other yeasts and ins...
11076748 - Isolation of radial glial cells by fluorescent-activated cell sorting reveals a neurona...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current oncology reports     Volume:  6     ISSN:  1523-3790     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-01-30     Completed Date:  2004-05-12     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  111-5     Citation Subset:  IM    
Affiliation:
Our Lady of Mercy Cancer Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA. jpd4401@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antineoplastic / pharmacology,  therapeutic use*
Cell Division / drug effects
Cell Line, Tumor
Clinical Trials as Topic
Drug Evaluation, Preclinical
Humans
Neoplasms / drug therapy*,  genetics
Protein Kinase Inhibitors*
Protein Kinases*
Sirolimus / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Protein Kinase Inhibitors; 53123-88-9/Sirolimus; EC 2.7.-/Protein Kinases; EC 2.7.1.-/mTOR protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular targeting agents.
Next Document:  Glutathione analogues in cancer treatment.